International trials of olaparib were stopped early as benefits of ‘groundbreaking’ drug became clear
Women with hereditary breast cancer, triggered by the BRCA1 or BRCA2 genes, stand a better chance of survival following successful trials of a drug that cuts the likelihood of the cancer returning after treatment.
A major trial carried out by academic researchers to see whether olaparib can prevent recurrence was stopped early – after two-and-a-half years instead of the planned 10 years – when the benefits of the drug became clear.
